July 23, 2026
1 min read

FDA rebukes 2 Indian API plants over data controls, sanitation issues

The FDA slammed a pair of India-based API manufacturers in separate warning letters outlining poor record-keeping, problems maintaining sanitation and licensing issues, among other observations.

Leave a Reply

Your email address will not be published.

Previous Story

Pets at Home Celebrates the Perfect Poo in Nutrition Campaign

Next Story

STAT+: FDA staff and peptide enthusiasts set to clash at advisory panel

Previous Story

Pets at Home Celebrates the Perfect Poo in Nutrition Campaign

Next Story

STAT+: FDA staff and peptide enthusiasts set to clash at advisory panel

Latest from Blog

Go toTop